Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2004

View Archived Issues

Esperion Therapeutics plans to develop therapies based on PPARdelta agonists

Helsinn and Taiho sign an agreement for palonosetron

Interim data on the effects of GTI-2040 and capecitabine in advanced renal cell cancer

Once monthly ibandronate found effective in the management of osteoporosis

New phase II results described for NGD-2000-1 in asthma

OyaGen, a new company to develop a novel class of HIV drugs

Sucampo completes a new phase III clinical trial with SPI-0211 in constipation

Good safety and pharmacokinetic data reported for XP-13512 in healthy volunteers

Novel antibacterial macrolides under investigation at Janssen

Vertex claims JAK/CDK2 inhibitors for allergic and immune disorders

Merck presents new inhibitors of B. anthracis lethal factor

Galderma describes two series of RAR antagonists for dermatological disorders

AstraZeneca presents new CRTh2 modulators with utility in respiratory disorders

New antibacterial PDF inhibitors covered by GSK patent

NeuroSearch team describes dual nAChR/monoamine transporter modulators

Xenon Genetics selects clinical candidates for metabolic syndrome program

Cytos' Immunodrug for nicotine addiction enters phase II trial in smokers

Women's Health Connecticut adopts use of Digene's DNAwithPap Test

LUMC and OctoPlus to evaluate new drug for chronic middle ear infection

Watson launches generic sustained-release bupropion hydrochloride

Phase III eflornithine trial in superficial bladder cancer discontinued

PTC Therapeutics raises funds to support development of PTC-124

CP-690550 demonstrates immunosuppressive potential in mice

Fujisawa, AtheroGenics to jointly develop transplant rejection treatment AGI-1096

Revenues increase at Genzyme

CytRx funds RNA interference research for CMV disease treatment

WAY-135433 promotes HDL cholesterol increase

AFP-168, a novel ocular hypotensive candidate

Academic researchers discover novel SERM with CNS effects

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...